Hydrogen sulfide attenuates disturbed flow-induced vascular remodeling by inhibiting LDHB-mediated autophagic flux

Xia Wang1, Xiying Huang1, Yongya Zhang2

  • 1Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, China.

Redox Biology
|December 8, 2024
PubMed

Insights

Hydrogen sulfide (H2S) donor NaHS prevents cardiovascular disease progression by suppressing disturbed flow-induced vascular remodeling. It inhibits vascular smooth muscle cell proliferation and migration by targeting lactate dehydrogenase B (LDHB).

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biochemistry

Background:

  • Disturbed flow (DF) is a key factor in cardiovascular disease (CVD) development and progression.
  • Hydrogen sulfide (H2S) has known cardiovascular functions, but its role in DF-induced vascular remodeling is not fully understood.

Purpose of the Study:

  • To investigate the protective mechanisms of H2S against DF-induced vascular remodeling.
  • To elucidate the molecular pathways involved in H2S-mediated cardiovascular protection.

Main Methods:

  • Used a mouse model of DF-induced vascular remodeling.
  • Administered H2S donor (NaHS) and assessed its effects on vascular remodeling, VSMC proliferation, migration, and autophagy.
  • Employed RNA-sequencing (RNA-Seq) to identify molecular targets, followed by overexpression studies and protein interaction analysis (LDHB and ATP6V1A).

Main Results:

  • NaHS significantly suppressed DF-induced vascular remodeling and VSMC proliferation/migration.
  • NaHS inhibited DF- and PDGF-induced autophagy by downregulating lactate dehydrogenase B (LDHB) and disrupting its interaction with ATP6V1A.
  • Elevated LDHB expression was observed in human aortic aneurysm tissues (AAA and TAA).

Conclusions:

  • H2S attenuates DF-induced vascular remodeling by inhibiting LDHB, disrupting the LDHB-ATP6V1A interaction, and impeding autophagy.
  • Targeting LDHB or utilizing H2S presents a potential therapeutic strategy for vascular remodeling and related cardiovascular diseases.